{"nct_id":"NCT04128696","title":"Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","status_verified_date":"2024-06","start_date":"2019-11-21","start_date_type":"ACTUAL","primary_completion_date":"2021-04-27","primary_completion_date_type":"ACTUAL","completion_date":"2023-06-20","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GSK"]}